<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link href='https://unpkg.com/boxicons@2.1.4/css/boxicons.min.css' rel='stylesheet'>
    <title>Disease</title>
    <link rel="stylesheet" href="About_D.css">
</head>
<body>
    <div class="ALD">
        <div class="navigator">
            <h1 class="navheading">Neurodegenerative Diseases</h1>
        </div>
        <div id="disease_tab1" class="maincolumn">
            <h2 class="diseasetitle">Amyotrophic Lateral Sclerosis (ALS)</h2>
            <p class="aboutdisease"> It is a progressive disease-causing muscle weakness and paralysis by damaging motor neurons in the brain and spinal cord.</p>
            <table class="tablecontents">
                <tr>
                    <th>Drug Names</th>
                    <th>Newest Drugs</th>
                    <th>Diagnosis</th>
                    <th>Treatment</th>
                    <th>Recent Advances</th>
                </tr>
                <tr>
                    <td> 
                        <ul>
                            <li><b>Riluzole</b> (Exservan, Rilutek, Tiglutik)</li>
                            <li><b>Qalsody</b> (Tofersen, BIIB067)</li>
                            <li><b>Radicava</b> (Edaravone)</li>
                            <li><b>Nuedexta</b> (Dextromethorphan HBr and Quinidine Sulfate)</li>
                        </ul>
                    </td>
                    <td>
                        Not Available right now.
                    </td>
                    <td>
                        <ul>
                            <li><b>Clinical Exam:</b> Identifies progressive weakness and motor dysfunction.</li>
                            <li><b>EMG & NCS:</b> Confirms motor neuron damage, excludes nerve disorders.</li>
                            <li><b>MRI:</b> Rules out structural brain or spine issues.</li>
                            <li><b>Blood/Genetic Tests:</b> Screens for mimicking diseases and ALS-linked mutations.</li>
                            <li><b>El Escorial Criteria:</b> Validates ALS by motor neuron involvement in multiple regions.</li>
                        </ul>
                    </td>
                    <td>
                        <ul>
                            <li><b>medications:</b> Riluzole (Slows progression)-Edaravone (Reduces oxidative stress)</li>
                            <li><b>Symptom Management:</b> Muscle relaxants, antidepressants, and pain relief.</li>
                            <li><b>therapies:</b> Physical, occupational, speech therapy.</li>
                            <li><b>nutrition:</b> High-calorie diet, feeding tubes.</li>
                            <li><b>Respiratory Support:</b> BiPAP, mechanical ventilation.</li>
                            <li><b>Multidisciplinary Care:</b> Neurologists, therapists, dietitians, palliative care.</li>
                        </ul>
                    </td>
                    <td>
                        <ul>
                            <li><b>biomarkers:</b> Predict drug response for personalized care.</li>
                            <li><b>neuroimaging:</b> Reveals CNS changes in ALS.</li>
                            <li><b>Stem Cell Therapy:</b> Spinal cord injections show potential in slowing disease progression.</li>
                            <li><b>Assistive Tech:</b> Tools enhance daily living.</li>
                            <li><b>Synapse Regeneration:</b> SPG302, a pill targeting synapse repair, is in phase 2 trial.</li>
                        </ul>
                    </td>
                </tr>
            </table>
        </div>
    </div>
    <script src="neuro.js"></script>
</body>
</html>